Citation for FEvIR Evidence 7637: Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill COVID-19 - Evidence Based Medicine on FHIR Implementation Guide v1.0.0-ballot

This page is part of the Evidence Based Medicine on FHIR Implementation Guide (v1.0.0-ballot: STU1 Ballot 1) based on FHIR (HL7® FHIR® Standard) v5.0.0. . For a full list of available versions, see the Directory of published versions

Example Citation: Citation for FEvIR Evidence 7637: Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill COVID-19

Active as of 2022-01-10

Generated Narrative: Citation

Resource Citation "7638" Version "32" Updated "2023-12-02 12:42:05+0000"

StructureDefinition Work Group: cds

url: https://fevir.net/resources/Citation/7638

identifier: FEvIR Object Identifier: 7638

version: 1.0.0-ballot

title: Citation for FEvIR Evidence 7637: Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill COVID-19

status: active

date: 2022-01-10 13:30:43+0000

publisher: HL7 International / Clinical Decision Support

contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss

description: A Evidence Resource to demonstrate complex evidence reporting

UseContexts

Code

Value[x]

Program (Details: http://terminology.hl7.org/CodeSystem/usage-context-type code program = 'Program', stated as 'Program')

EBMonFHIR/COKA Demonstration ()

FEvIR Platform Use (Details: http://hl7.org/fhir/citation-classification-type code fevir-platform-use = 'FEvIR Platform Use', stated as 'FEvIR Platform Use')

Evidence (Citation Artifact Classifier#fhir-resource "FHIR Resource")

jurisdiction: World (m49.htm#001)

copyright: https://creativecommons.org/licenses/by-nc-sa/4.0/

author: Brian S. Alper:

Summaries

Style

Text

Computable Publishing (Citation Summary Style#comppub)

Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19 [FHIR Resource]. Contributors: Brian S Alper, Harold Lehmann, Ahmad Sofi-Mahmudi, Joanne Dehnbostel, Ilkka Kunnamo [Authors]; Janice Tufte, Vignesh Subbian, Bhagvan Kommadi, Alfonso Iorio, Muhammad Afzal, Kenneth J Wilkins, Surbhi Shah, Amy Price [Reviewers]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 7637. Published August 05, 2021. Created August 05, 2021. Revised August 25, 2021. Available at: https://fevir.net/resources/Evidence/7637. Computable resource at: https://fevir.net/resources/Evidence/7637.

Classifications

Type

Classifier

FEvIR Platform Use (Citation Classification Type#fevir-platform-use)

Project Specific (Citation Artifact Classifier#project-specific)

citedArtifact
identifier: FEvIR Object Identifier: 7637
relatedIdentifier: id: 10.1056/NEJMoa2105911
StatusDates
- Activity Actual Period
* Created (Cited Artifact Status Type#created) true 2021-08-05 --> (ongoing)
title
type: Primary title (Title Type#primary), Human use (Title Type#human-use)
language: English (Tags for the Identification of Languages#en)
text: Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19
title
type: Different text in an earlier version (Title Type#earlier-title)
language: English (Tags for the Identification of Languages#en)
text: Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill COVID-19
abstract
type: Description (Evidence Based Medicine on FHIR Implementation Guide Code System#description)
language: English (Tags for the Identification of Languages#en)
text: Patients who were hospitalized for COVID-19 and who were not critically ill were randomized in a response-adaptive manner to therapeutic-dose anticoagulation with heparin vs. usual-care pharmacologic thromboprophylaxis. The outcome reported here is the effect on organ support-free days (i.e. days without oxygen delivered by high-flow nasal cannula, noninvasive or invasive mechanical ventilation, or the use of vasopressors or inotropes). The statistical result was a median adjusted odds ratio 1.27 (95% credible interval 1.03 to 1.58), based on 1,740 events among 2,219 participants with known outcome out of 2,244 enrolled participants. The probability of superiority of therapeutic-dose anticoagulation with heparin was 98.6%. The risk of bias in this effect estimate is of extremely serious concern based on a serious concern for confounding covariate bias (confounding difference in calendar time), a very serious concern for performance bias (inadequate blinding of intervention deliverers who may determine the outcome based in part on exposure status), and very serious concern for analysis bias (bias related to selection of the analysis, and early trial termination).
abstract
type: Assertion (Evidence Based Medicine on FHIR Implementation Guide Code System#assertion)
language: English (Tags for the Identification of Languages#en)
text: It is uncertain whether therapeutic-dose anticoagulation with heparin affects the rate of organ support-free days in hospitalized patients with COVID-19 who are not critically ill.
relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 [Journal Article]. Contributors: The ATTACC, ACTIV-4a, and REMAP-CAP Investigators. In: The New England Journal of Medicine, DOI 10.1056/NEJMoa2105911. Published August 04, 2021. Available at: https://doi.org/10.1056/NEJMoa2105911.
Documents
- Url
* Anticoagulation for COVID-19 Combined RCTs in NEJM
resourceReference: FEvIR Object Identifier: 7636
publicationForm
PublishedIns
- Type Title Publisher PublisherLocation
* Database (Published In Type#D019991) Fast Evidence Interoperability Resources (FEvIR) Platform : Computable Publishing LLC Ipswich, MA, USA
articleDate: 2021-08-05
lastRevisionDate: 2021-08-25
language: English (Tags for the Identification of Languages#en)
copyright: https://creativecommons.org/licenses/by-nc-sa/4.0/
WebLocations
- Classifier Url
* Computable resource (Artifact Url Classifier#computable-resource), JSON (Artifact Url Classifier#json) Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19
classification
type: Knowledge Artifact Type (Cited Artifact Classification Type#knowledge-artifact-type)
classifier: FHIR Resource (Citation Artifact Classifier#fhir-resource)
classification
type: fhir-resource (Citation Artifact Classifier#fhir-resource "FHIR Resource")
classifier: Evidence (All FHIR Types#Evidence)
contributorship
complete: true
entry
contributor:

identifier: id: 0000-0003-4300-4928
name: Brian S Alper
telecom: balper@computablepublishing.com
forenameInitials: BS
affiliation:
: Computable Publishing LLC
: Scientific Knowledge Accelerator Foundation
: COVID-19 Knowledge Accelerator
contributionType: Conceptualization (Artifact Contribution Type#conceptualization), Data curation (Artifact Contribution Type#data-curation), Investigation (Artifact Contribution Type#investigation), Methodology (Artifact Contribution Type#methodology), Software (Artifact Contribution Type#software), Writing - original draft (Artifact Contribution Type#writing-original-draft)
role: Author/Creator (Contributor Role#author)
ContributionInstances
- Type Time
* Risk of bias assessment (Evidence Based Medicine on FHIR Implementation Guide Code System#defined-in-text "Defined in text") 2021-08-05
correspondingContact: true
entry
contributor:

identifier: id: 0000-0002-4346-3238
name: Janice Tufte
telecom: hassanahseattle@gmail.com
affiliation: : Hassanah Consulting
contributionType: Writing - review & editing (Artifact Contribution Type#writing-review-editing), Formal analysis (Artifact Contribution Type#formal-analysis), Investigation (Artifact Contribution Type#investigation), Validation (Artifact Contribution Type#validation)
role: Reviewer (Contributor Role#reviewer)
contributionInstance
type: Reviewed (Artifact Contribution Instance Type#reviewed)
time: 2021-08-05
contributionInstance
type: Reviewed (Artifact Contribution Instance Type#reviewed)
time: 2021-08-06
entry
contributor:

name: Harold Lehmann
telecom: lehmann@jhmi.edu
affiliation: : Johns Hopkins University
contributionType: Investigation (Artifact Contribution Type#investigation), Methodology (Artifact Contribution Type#methodology), Writing - original draft (Artifact Contribution Type#writing-original-draft)
role: Author/Creator (Contributor Role#author)
entry
contributor:

name: Ahmad Sofi-Mahmudi
telecom: a.sofimahmudi@gmail.com
affiliation: : Cochrane Iran Associate Centre
contributionType: Investigation (Artifact Contribution Type#investigation), Methodology (Artifact Contribution Type#methodology), Validation (Artifact Contribution Type#validation), Writing - review & editing (Artifact Contribution Type#writing-review-editing)
role: Author/Creator (Contributor Role#author)
entry
contributor:

name: Joanne Dehnbostel
telecom: jdehnbostel@computablepublishing.com
affiliation: : Computable Publishing LLC
contributionType: Project administration (Artifact Contribution Type#project-administration), Investigation (Artifact Contribution Type#investigation), Writing - review & editing (Artifact Contribution Type#writing-review-editing)
role: Author/Creator (Contributor Role#author)
entry
contributor:

name: Vignesh Subbian
telecom: vsubbian@arizona.edu
affiliation: : University of Arizona
contributionType: Formal analysis (Artifact Contribution Type#formal-analysis), Investigation (Artifact Contribution Type#investigation), Writing - review & editing (Artifact Contribution Type#writing-review-editing)
role: Reviewer (Contributor Role#reviewer)
ContributionInstances
- Type Time
* Reviewed (Artifact Contribution Instance Type#reviewed) 2021-08-07
entry
contributor:

identifier: id: 0000-0002-4817-6991
name: Ilkka Kunnamo
telecom: ilkka.kunnamo@duodecim.fi
affiliation:
: Duodecim Medical Publications Ltd., Finland
: Scientific Knowledge Accelerator Foundation
contributionType: Writing - review & editing (Artifact Contribution Type#writing-review-editing)
role: Author/Creator (Contributor Role#author)
ContributionInstances
- Type Time
* Reviewed (Artifact Contribution Instance Type#reviewed) 2021-08-09
entry
contributor:

name: Bhagvan Kommadi
telecom: bhagvanarch@gmail.com
affiliation: : Value Momentum
contributionType: Methodology (Artifact Contribution Type#methodology), Validation (Artifact Contribution Type#validation)
role: Reviewer (Contributor Role#reviewer)
entry
contributor:

name: Alfonso Iorio
affiliation: : McMaster University
contributionType: Formal analysis (Artifact Contribution Type#formal-analysis), Writing - review & editing (Artifact Contribution Type#writing-review-editing)
role: Reviewer (Contributor Role#reviewer)
entry
contributor:

name: Muhammad Afzal
telecom: afzalse@gmail.com
affiliation: : Sejong University, Seoul, South Korea
contributionType: Formal analysis (Artifact Contribution Type#formal-analysis), Writing - review & editing (Artifact Contribution Type#writing-review-editing)
role: Reviewer (Contributor Role#reviewer)
entry
contributor:

name: Kenneth J Wilkins
affiliation: : National Institute of Diabetes & Digestive & Kidney Diseases
contributionType: Formal analysis (Artifact Contribution Type#formal-analysis), Writing - review & editing (Artifact Contribution Type#writing-review-editing)
role: Reviewer (Contributor Role#reviewer)
entry
contributor:

name: Surbhi Shah
affiliation: : Mayo Clinic Arizona
contributionType: Writing - review & editing (Artifact Contribution Type#writing-review-editing), Clinical commentary (Evidence Based Medicine on FHIR Implementation Guide Code System#defined-in-text "Defined in text")
role: Reviewer (Contributor Role#reviewer)
entry
contributor:

name: Amy Price
contributionType: Writing - review & editing (Artifact Contribution Type#writing-review-editing)
role: Reviewer (Contributor Role#reviewer)

Generated Narrative: Practitioner #contributor0
identifier: id: 0000-0003-4300-4928
name: Brian S Alper
telecom: balper@computablepublishing.com

Generated Narrative: Practitioner #contributor1
identifier: id: 0000-0002-4346-3238
name: Janice Tufte
telecom: hassanahseattle@gmail.com

Generated Narrative: Practitioner #contributor2
name: Harold Lehmann
telecom: lehmann@jhmi.edu

Generated Narrative: Practitioner #contributor3
name: Ahmad Sofi-Mahmudi
telecom: a.sofimahmudi@gmail.com

Generated Narrative: Practitioner #contributor4
name: Joanne Dehnbostel
telecom: jdehnbostel@computablepublishing.com

Generated Narrative: Practitioner #contributor5
name: Vignesh Subbian
telecom: vsubbian@arizona.edu

Generated Narrative: Practitioner #contributor6
identifier: id: 0000-0002-4817-6991
name: Ilkka Kunnamo
telecom: ilkka.kunnamo@duodecim.fi

Generated Narrative: Practitioner #contributor7
name: Bhagvan Kommadi
telecom: bhagvanarch@gmail.com

Generated Narrative: Practitioner #contributor8
name: Alfonso Iorio

Generated Narrative: Practitioner #contributor9
name: Muhammad Afzal
telecom: afzalse@gmail.com

Generated Narrative: Practitioner #contributor10
name: Kenneth J Wilkins

Generated Narrative: Practitioner #contributor11
name: Surbhi Shah

Generated Narrative: Practitioner #contributor12
name: Amy Price